Related Experiment Video

Updated: Aug 21, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Digoxin may reduce the mortality rates in patients with congestive heart failure

Lexin Wang1, Shukai Song

  • 1School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia. lwang@csu.edu.au

Medical Hypotheses
|November 10, 2004
PubMed

Insights

Maintaining lower digoxin serum concentrations (0.5-0.8 ng/ml) may improve outcomes for congestive heart failure (CHF) patients. This approach could reduce mortality and improve symptoms, unlike higher levels linked to increased risks.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Digoxin has a long history in treating congestive heart failure (CHF).
  • Recent trials question digoxin's mortality benefits in CHF, showing only modest symptom improvement and reduced hospitalizations.
  • High digoxin serum concentrations (>or=1.2 ng/ml) are linked to increased all-cause mortality in CHF patients.

Purpose of the Study:

  • To investigate the hypothesis that digoxin serum concentration is a key factor in its effect on mortality rates in CHF patients.
  • To determine if maintaining lower digoxin serum concentrations can reduce mortality and improve clinical symptoms.

Main Methods:

  • The study focuses on analyzing the relationship between digoxin serum concentrations and mortality/symptom outcomes in CHF patients.
  • It reviews existing clinical trial data and pharmacological principles.

Main Results:

  • Higher digoxin serum concentrations are associated with increased mortality risk in heart failure patients.
  • Potential mechanisms for increased risk at higher concentrations include elevated myocardial oxygen consumption and arrhythmogenesis.

Conclusions:

  • Maintaining digoxin serum concentrations at the lower end of the therapeutic range (0.5-0.8 ng/ml) may be crucial for improving outcomes.
  • This targeted concentration range has the potential to reduce mortality rates and enhance clinical symptom management in CHF patients.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...